vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $50.4M, roughly 1.7× Armour Residential REIT, Inc.). On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 108.0%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ARR vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $86.8M |
| Net Profit | $211.7M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 420.2% | — |
| Revenue YoY | 297.9% | 17.7% |
| Net Profit YoY | 555.9% | — |
| EPS (diluted) | $2.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $86.8M | ||
| Q3 25 | $38.5M | $67.5M | ||
| Q2 25 | $33.1M | $60.0M | ||
| Q1 25 | $36.3M | $49.3M | ||
| Q4 24 | $12.7M | $73.7M | ||
| Q3 24 | — | $58.6M | ||
| Q2 24 | $7.0M | $31.1M | ||
| Q1 24 | — | $715.0K |
| Q4 25 | $211.7M | — | ||
| Q3 25 | $159.3M | $-91.3M | ||
| Q2 25 | $-75.6M | $-111.7M | ||
| Q1 25 | $27.3M | $-116.2M | ||
| Q4 24 | $-46.4M | — | ||
| Q3 24 | — | $-83.5M | ||
| Q2 24 | $-48.4M | $-97.1M | ||
| Q1 24 | — | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -84.7% | ||
| Q3 25 | — | -140.7% | ||
| Q2 25 | — | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | — | -152.1% | ||
| Q2 24 | — | -327.6% | ||
| Q1 24 | — | -16464.6% |
| Q4 25 | 420.2% | — | ||
| Q3 25 | 413.5% | -135.3% | ||
| Q2 25 | -228.4% | -186.2% | ||
| Q1 25 | 75.2% | -235.5% | ||
| Q4 24 | -366.8% | — | ||
| Q3 24 | — | -142.7% | ||
| Q2 24 | -693.8% | -312.2% | ||
| Q1 24 | — | -15800.8% |
| Q4 25 | $2.43 | — | ||
| Q3 25 | $1.49 | — | ||
| Q2 25 | $-0.94 | $-0.33 | ||
| Q1 25 | $0.32 | $-0.36 | ||
| Q4 24 | $-0.91 | $-0.24 | ||
| Q3 24 | — | $-0.28 | ||
| Q2 24 | $-1.05 | $-0.34 | ||
| Q1 24 | — | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $698.6M |
| Total Assets | $21.0B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $297.0M | ||
| Q3 25 | $44.2M | $300.8M | ||
| Q2 25 | $141.2M | $301.2M | ||
| Q1 25 | $49.1M | $359.7M | ||
| Q4 24 | $68.0M | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | $126.6M | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $2.3B | $698.6M | ||
| Q3 25 | $2.1B | $702.3M | ||
| Q2 25 | $1.7B | $698.5M | ||
| Q1 25 | $1.7B | $767.9M | ||
| Q4 24 | $1.4B | $710.4M | ||
| Q3 24 | — | $773.5M | ||
| Q2 24 | $1.2B | $768.5M | ||
| Q1 24 | — | $680.0M |
| Q4 25 | $21.0B | $913.2M | ||
| Q3 25 | $19.4B | $904.9M | ||
| Q2 25 | $16.2B | $907.4M | ||
| Q1 25 | $15.5B | $966.7M | ||
| Q4 24 | $13.5B | $910.4M | ||
| Q3 24 | — | $991.1M | ||
| Q2 24 | $10.1B | $964.3M | ||
| Q1 24 | — | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-52.6M | ||
| Q3 25 | $-37.8M | $-78.7M | ||
| Q2 25 | $25.0M | $-67.4M | ||
| Q1 25 | $101.5M | $-103.7M | ||
| Q4 24 | $261.5M | $-73.3M | ||
| Q3 24 | — | $-59.0M | ||
| Q2 24 | $27.1M | $-98.4M | ||
| Q1 24 | — | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARR
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
